Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | DRD2 | P14416 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL41857 | 0.74 | ALDH1A1 (0.45) | ALDH1A1GAAMEN1GLAKMT2A | |
| SCHEMBL25532698 | 0.73 | MEN1 (0.43) | GAAMEN1KMT2ARAB9A | |
| SCHEMBL2683841 | 0.71 | MEN1 (0.57) | GAAMEN1KMT2ADRD2 | |
| SCHEMBL24831465 | 0.70 | CTSS (0.50) | GAAMEN1KMT2ARAB9A | |
| SCHEMBL39912 | 0.70 | CYP3A4 (0.53) | ALDH1A1MEN1KMT2ALMNARAB9A | |
| SCHEMBL10377809 | 0.69 | NPC1 (0.46) | ALDH1A1MEN1KMT2ALMNARAB9A | |
| SCHEMBL10377815 | 0.69 | NPC1 (0.46) | ALDH1A1MEN1KMT2ALMNARAB9A | |
| SCHEMBL6610694 | 0.69 | NPC1 (0.46) | ALDH1A1MEN1KMT2ALMNARAB9A | |
| SCHEMBL12437163 | 0.68 | ALDH1A1 (0.46) | ALDH1A1GAAMEN1GLAKMT2A | |
| SCHEMBL26057650 | 0.68 | ALDH1A1 (0.54) | ALDH1A1TSHRRAB9AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120028990-A1 | 3 ARYL OR HETEROARYL-SUBSTITUTED INDOLE DERIVATIVE | MSD K.K | 2012-02-02 | — | — | US | disclosed |
| US-20120028990-A1 | 3 ARYL OR HETEROARYL-SUBSTITUTED INDOLE DERIVATIVE | MSD K.K | 2012-02-02 | — | — | US | disclosed |
| WO-2010119984-A1 | 3-ARYL OR HETEROARYL-SUBSTITUTED INDOLE DERIVATIVE | BANYU PHARMACEUTICAL CO.,LTD. (JP) | 2010-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028990-A1 | 3 ARYL OR HETEROARYL-SUBSTITUTED INDOLE DERIVATIVE | IDO1, TPH1, AHR | ALDH1A1 2066/4885GAA 2702/4885MEN1 886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.